Quantitative susceptibility mapping reveals alterations of dentate nuclei in common types of degenerative cerebellar ataxias.
MRI
ataxia
cerebellum
iron
quantitative susceptibility mapping
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
12
2021
revised:
28
10
2021
accepted:
05
01
2022
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
17
3
2022
Statut:
epublish
Résumé
The cerebellar nuclei are a brain region with high iron content. Surprisingly, little is known about iron content in the cerebellar nuclei and its possible contribution to pathology in cerebellar ataxias, with the only exception of Friedreich's ataxia. In the present exploratory cross-sectional study, quantitative susceptibility mapping was used to investigate volume, iron concentration and total iron content of the dentate nuclei in common types of hereditary and non-hereditary degenerative ataxias. Seventy-nine patients with spinocerebellar ataxias of types 1, 2, 3 and 6; 15 patients with Friedreich's ataxia; 18 patients with multiple system atrophy, cerebellar type and 111 healthy controls were also included. All underwent 3 T MRI and clinical assessments. For each specific ataxia subtype, voxel-based and volumes-of-interest-based group analyses were performed in comparison with a corresponding age- and sex-matched control group, both for volume, magnetic susceptiblity (indicating iron concentration) and susceptibility mass (indicating total iron content) of the dentate nuclei. Spinocerebellar ataxia of type 1 and multiple system atrophy, cerebellar type patients showed higher susceptibilities in large parts of the dentate nucleus but unaltered susceptibility masses compared with controls. Friedreich's ataxia patients and, only on a trend level, spinocerebellar ataxia of type 2 patients showed higher susceptibilities in more circumscribed parts of the dentate. In contrast, spinocerebellar ataxia of type 6 patients revealed lower susceptibilities and susceptibility masses compared with controls throughout the dentate nucleus. Spinocerebellar ataxia of type 3 patients showed no significant changes in susceptibility and susceptibility mass. Lower volume of the dentate nuclei was found to varying degrees in all ataxia types. It was most pronounced in spinocerebellar ataxia of type 6 patients and least prominent in spinocerebellar ataxia of type 3 patients. The findings show that alterations in susceptibility revealed by quantitative susceptibility mapping are common in the dentate nuclei in different types of cerebellar ataxias. The most striking changes in susceptibility were found in spinocerebellar ataxia of type 1, multiple system atrophy, cerebellar type and spinocerebellar ataxia of type 6. Because iron content is known to be high in glial cells but not in neurons of the cerebellar nuclei, the higher susceptibility in spinocerebellar ataxia of type 1 and multiple system atrophy, cerebellar type may be explained by a reduction of neurons (increase in iron concentration) and/or an increase in iron-rich glial cells, e.g. microgliosis. Hypomyelination also leads to higher susceptibility and could also contribute. The lower susceptibility in SCA6 suggests a loss of iron-rich glial cells. Quantitative susceptibility maps warrant future studies of iron content and iron-rich cells in ataxias to gain a more comprehensive understanding of the pathogenesis of these diseases.
Identifiants
pubmed: 35291442
doi: 10.1093/braincomms/fcab306
pii: fcab306
pmc: PMC8914888
doi:
Types de publication
Journal Article
Comment
Langues
eng
Pagination
fcab306Commentaires et corrections
Type : CommentOn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
PLoS One. 2015 Jul 31;10(7):e0133402
pubmed: 26230510
Cerebellum. 2012 Sep;11(3):749-60
pubmed: 22198871
Neuroimage. 2016 Feb 15;127:435-444
pubmed: 26408861
Hum Brain Mapp. 2021 Apr 1;42(5):1463-1474
pubmed: 33378095
J Neurophysiol. 2003 Jan;89(1):634-9
pubmed: 12522208
Lancet Neurol. 2019 Jul;18(7):631-642
pubmed: 31202468
Lancet Neurol. 2014 Oct;13(10):1045-60
pubmed: 25231526
J Comp Neurol. 2002 Oct 28;452(4):311-23
pubmed: 12355415
Neurobiol Dis. 2015 Sep;81:108-18
pubmed: 25801802
Neuroscience. 2015 Mar 19;289:289-99
pubmed: 25595967
Neuroimage. 2012 Feb 1;59(3):2625-35
pubmed: 21925274
J Neurol. 2016 Nov;263(11):2215-2223
pubmed: 27522354
Ann Neurol. 1996 Feb;39(2):241-55
pubmed: 8967756
PLoS One. 2015 Mar 04;10(3):e0116396
pubmed: 25738292
J Comp Neurol. 1993 Dec 1;338(1):97-113
pubmed: 8300902
J Alzheimers Dis. 2018;62(3):1141-1179
pubmed: 28984582
Cerebellum. 2019 Jun;18(3):435-447
pubmed: 30771164
NMR Biomed. 2017 Apr;30(4):
pubmed: 27434134
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Neuroimage. 2009 Jan 1;44(1):83-98
pubmed: 18501637
J Neurol Neurosurg Psychiatry. 2019 May;90(5):615-617
pubmed: 29945881
Brain. 1991 Aug;114 ( Pt 4):1953-75
pubmed: 1832073
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Mov Disord. 2019 Mar;34(3):335-343
pubmed: 30624809
J Mol Biol. 2019 Apr 19;431(9):1792-1804
pubmed: 30660620
Handb Clin Neurol. 2012;103:399-421
pubmed: 21827903
Neuroimage. 2011 Feb 1;54(3):1786-94
pubmed: 20965257
Z Med Phys. 2019 May;29(2):128-138
pubmed: 30579766
J Clin Neurosci. 2010 Jun;17(6):751-5
pubmed: 20359894
Neurodegener Dis. 2011;8(6):470-5
pubmed: 21659723
Appl Opt. 2007 Sep 10;46(26):6623-35
pubmed: 17846656
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Hum Brain Mapp. 2014 Jun;35(6):2698-713
pubmed: 24038837
J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):98-101
pubmed: 8558163
J Magn Reson Imaging. 2010 Jan;31(1):192-203
pubmed: 20027588
Ann Neurol. 1999 Jul;46(1):123-5
pubmed: 10401790
AJNR Am J Neuroradiol. 2017 Aug;38(8):1467-1474
pubmed: 28408628
Neuroimage. 2011 Jun 1;56(3):930-8
pubmed: 21320606
Acta Neuropathol. 1998 Feb;95(2):199-204
pubmed: 9498057
J Neuroinflammation. 2017 May 25;14(1):107
pubmed: 28545543
Cerebellum. 2013 Jun;12(3):418-28
pubmed: 23090211
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19538-19543
pubmed: 32723827
Neurology. 1995 Jan;45(1):24-30
pubmed: 7824128
J Alzheimers Dis. 2018;61(4):1253-1273
pubmed: 29376857
J Neurol Sci. 2019 Dec 15;407:116525
pubmed: 31639532
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9843-8
pubmed: 15210960
Neuroimage. 2004 Aug;22(4):1732-43
pubmed: 15275929
J Neuropathol Exp Neurol. 1998 Sep;57(9):814-21
pubmed: 9737544
Neuroimage. 2011 Feb 14;54(4):2789-807
pubmed: 21040794
Neurology. 2008 Sep 23;71(13):982-9
pubmed: 18685131
J Comp Neurol. 1994 May 1;343(1):183-92
pubmed: 8027435
Blood. 2007 Jul 1;110(1):401-8
pubmed: 17379741
Med Phys. 2010 Oct;37(10):5165-78
pubmed: 21089750
Neuroimage. 2013 Sep;78:68-74
pubmed: 23591072
Cerebellum. 2012 Dec;11(4):845-60
pubmed: 22562713
Neurobiol Dis. 2016 Jan;85:262-274
pubmed: 25766679
Brain. 2017 Jan;140(1):118-131
pubmed: 27836833
Neuroimage Clin. 2014 Aug 23;6:93-9
pubmed: 25379420
J Neurochem. 1958 Oct;3(1):41-51
pubmed: 13611557
AJNR Am J Neuroradiol. 2009 Oct;30(9):1725-30
pubmed: 19541777
Neuroimage. 2012 Sep;62(3):2083-100
pubmed: 22659482
J Trace Elem Med Biol. 2014 Jan;28(1):13-7
pubmed: 24075790
J Med Imaging (Bellingham). 2019 Oct;6(4):044007
pubmed: 31824980
Pharmaceuticals (Basel). 2018 Sep 19;11(3):
pubmed: 30235822
Front Aging Neurosci. 2014 Oct 07;6:264
pubmed: 25339897
Acta Neuropathol. 2007 Aug;114(2):163-73
pubmed: 17443334
Glia. 1996 Jun;17(2):83-93
pubmed: 8776576
J Magn Reson Imaging. 2019 Jul;50(1):201-208
pubmed: 30511803
Ann N Y Acad Sci. 1999;890:7-25
pubmed: 10668410
Neuroimage. 2012 Sep;62(3):1593-9
pubmed: 22634862
Neurology. 2008 Aug 12;71(7):486-92
pubmed: 18695159
Science. 1997 Jun 13;276(5319):1709-12
pubmed: 9180083
Neuropathol Appl Neurobiol. 2009 Oct;35(5):515-27
pubmed: 19207264
Neuroimage. 2006 Oct 15;33(1):127-38
pubmed: 16904911
Neuroimage. 2019 Feb 15;187:77-92
pubmed: 29702183
Brain. 2015 May;138(Pt 5):1182-97
pubmed: 25818870